Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109382 · ClinicalTrials.gov registry record · Phase 2
Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)
A Phase 2 study, sponsored by University of Calgary.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT00109382 is a Phase 2 study that has completed, run by University of Calgary. The registered enrollment target is 500 participants.
The verdict
NCT00109382, a Phase 2 study, has completed, sponsored by University of Calgary.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
Current management of patients with TIA (transient ischemic attack) or minor stroke includes the prompt investigation and treatment in the days and weeks after the event. However, new evidence shows patients are at the highest risk of stroke in the first few days after the TIA, with 50% of strokes which happen in the three months following TIA occurring within 48-72 hours. To date, there is no evidence to guide physicians on how to safely reduce this risk. The FASTER trial is focusing on the initial period of high risk, starting patients on stroke prevention treatments in the hours following a TIA or minor stroke. The drugs to be tested have been shown to be effective in the similar setting of cardiology, reducing recurrent cardiac events in patients with unstable angina when commenced with the same speed after an event. All patients will be on aspirin. The trial will see if adding another drug, clopidogrel, has an additional benefit in reducing the number of strokes after TIA or minor stroke within three months of TIA or minor stroke. It will also look if the very early introduction of simvastatin, a cholesterol lowering therapy, reduces stroke after TIA or minor stroke, both by itself and in addition to clopidogrel. The final aim of the trial is to ensure that these treatments are safe to be used in this population of patients.
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
- DRUG Simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109382
The ClinicalTrials.gov registry entry for NCT00109382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Calgary, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aspirin is the first listed.
NCT00109382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109382 about?
NCT00109382 is a clinical study titled "Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)". Current management of patients with TIA (transient ischemic attack) or minor stroke includes the prompt investigation and treatment in the days and weeks after the event. However, new evidence shows patients are at the highest risk of stroke in the first few days after the TIA, with 50% of strokes w...
What is the current status of trial NCT00109382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2003-05. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00109382?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG), Simvastatin (DRUG).
Who is sponsoring clinical trial NCT00109382?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.